Abstract. The present study aimed to compare the clinical outcome of patients with coronary artery disease (CAD) who underwent a revascularization using conventional coronary angiography or a physiologically guided revascularization with Fractional Flow Reserve (FFR). Furthermore, outcomes in FFR guided percutaneous coronary intervention (PCI) and instantaneous wave-free ratio (iFR) guided PCI were compared. The analysis was performed for reported outcomes at a 1-year follow-up. After searching PubMed, EMBASE, and Web of Science for suitable publications, a total of 15,880 subjects were included. Comparing angiography guided and FFR guided PCI showed no significant difference in major adverse cardiac events [odds ratio (OR), 0.78; 95% confidence interval (CI), 0.59-1.04; P=0.09; I²=73%], death from any cause (OR, 0.74; 95% CI, 0.46-1.18; P= 0.20; I²=74%), myocardial infarction (OR, 0.93; 95% CI, 0.81-1.07; P= 0.31; I²= 0%) or unplanned revascularization (OR, 0.71; 95% CI, 0.41-1.23; P=0.22; I²=79%). In addition, no significant difference could be found between iFR and FFR guided PCI for major adverse cardiac events (OR, 0.97; 95% CI; 0.76-1.23; P= 0.81; I²= 0%), death from any cause (OR, 0.66; 95% CI, 0.40-1.11; P= 0.12; I²= 0%), myocardial infarction (OR, 0.83; 95% CI, 0.56-1.24; P= 0.37) or unplanned revascularization (OR, 1.16; 95% CI, 0.85-1.58; P=0.34; I²=16%). Overall, there was a tendency towards better outcomes of FFR in all four clinical endpoints compared with angiography guiding of PCI, and furthermore iFR showed no significant inferiority when compared to FFR in said clinical endpoints. When conducting a network meta-analysis, the results confirmed a non-inferiority of iFR compared to angiography guided revascularization.
Introduction
Finding the best course of treatment for coronary artery disease (CAD) is a recurring challenge in everyday clinical practice. Coronary revascularization is only justified for hemodynamically relevant stenosis (1, 2) . While coronary angiography can identify a coronary stenosis by conventional visual assessment, defining the functional hemodynamic significance of an intermediate stenosis can be difficult.
During cardiac catherization, the functional flow reserve (FFR) can be measured as the maximum available blood flow in a stenosed coronary segment. FFR is the current gold standard for deciding if revascularization is required in angiographically ambiguous coronary artery stenosis and is recommended by the 2014 ESC/EACTS guidelines on myocardial revascularization and the 2011 ACCF/AHA/SCAI guidelines for percutaneous coronary intervention (PCI) (3, 4) .
Despite this recommendation and the alleged benefits, the use of FFR is still limited. The administration of vasodilators such as adenosine, which is required to induce maximal hyperaemia when measuring FFR, can cause side effects (i.e. chest pain, dyspnoea, AV-blockage) during the procedure. Those side effects, cost and increased procedural time are preventing FFR from becoming a standard procedure in day-to-day clinical setting.
A rather new method used to determine the severity of a coronary stenosis is the instantaneous wave-free ratio (iFR). By identifying a period of naturally occurring constant peripheral resistance during diastole, there is no need for vasodilators (5) .
One-year clinical outcome of angiography, fractional flow reserve and instantaneous wave-free ratio guided percutaneous coronary intervention: A PRISMA-compliant meta-analysis
Several studies have shown similar diagnostic accuracy for FFR and iFR in the same coronary artery (5-7). Following the described comparable accuracy of FFR and iFR, the goal of this meta-analysis was to compare the clinical outcome of patients with CAD in which the stenosis was either evaluated visually by coronary angiography alone, or by hemodynamic assessment using FFR or iFR.
Materials and methods
Study design. This meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and is based on the review of previously published articles (8) (9) (10) (11) (12) (13) (14) (15) (16) . No ethical approval and patient consent were necessary.
Literature search. In July 2017 PubMed, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), were searched for studies evaluating the clinical outcomes of FFR and iFR. The keywords were 'fractional flow reserve' and 'myocardial' or 'fractional flow reserve' or 'wave-free ratio' or 'iFR and coronary' or 'FFR and coronary' with no other filter. No language restrictions were applied. We selected studies, which used a comparative analysis to identify a culprit coronary lesion.
Patient population with inclusion and exclusion criteria.
The following inclusion criteria were applied. The design was either a randomized clinical trial (RCT) or an observational study comparing either angiography and FFR guided or iFR and FFR guided PCI. Participants were adult (18 years and older) patients with indication for PCI. All data of one-year clinical outcomes (major adverse cardiac event (MACE), death from any cause, myocardial infarction (MI) or unplanned revascularization) could be retrieved from the published full text.
We applied the following exclusion criteria. The studies were not conducted on humans (studies on animals or in vitro systems). The literature presented results from a sub-study, was a duplicate or did not report clinical outcomes of angiography or FFR and iFR. All literature, that contained only diagnostic studies, surveys, reviews, case reports, comments, or meta-analysis. Three investigators (SB, ACS and VB) selected studies independently, and disagreements were resolved by discussion among all authors.
The following data of eligible studies were documented (Table I) : Name of the study, first author, year of publication, and details of the study design, characteristics of patients, data of clinical outcomes, and the studies were sorted by analyzed type of culprit assessment.
Statistical analysis. In case the extracted data was appropriate for pooled analysis, a meta-analysis was performed. Dichotomous data was analyzed using the Mantel-Haenszel model and reported as an odds ratio (OR). Forest plots were used for visualization of the results.
The heterogeneity of studies was calculated using the I² index. An I² value of 0-25% represents insignificant heterogeneity; >25-50% low heterogeneity; >50-75% moderate heterogeneity; and >75% high heterogeneity (17) . All results were calculated using a random-effects model. If concerns for high heterogeneity existed, a sensitivity analysis was performed. Funnel plots were used to visualize publication bias. For other bias, a risk of bias assessment figure was used (Fig. 1) . The comparison between angiography and iFR was performed with a network meta-analysis. For meta-analysis calculations, the Review Manager version 5.3 (The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark) and for network meta-analysis the SAS system release version 9.3 (SAS Institute Inc., Cary, NC, USA) was used. P<0.05 was considered to indicate a statistically significant difference.
Results
A total of 756 studies were screened, and nine studies were identified that fulfilled the previously determined inclusion criteria. A flow chart shows the selection process and the reasons for exclusion (Fig. 2) . A total of 694 articles were eliminated, since their titles or abstracts did not fit our inclusion criteria.
The full-texts of 62 articles were assessed and 53 were not included in the quantitative and qualitative analysis since they did not contain a one-year follow-up or only analyzed a single method of coronary artery lesion evaluation. In total, the remaining studies included 15,880 patients with a one-year follow-up for MACE after PCI. Five studies and 8,403 patients were used for the analysis of angiography guided PCI, seven studies with 5,223 patients were used to analyze the FFR guided PCI and two studies with 2,254 patients were used for analysis of the iFR guided PCI. The exact number of patients for each study can be seen in Table I .
Overall, the nine studies did not have significant differences regarding patient baseline characteristics, which can be seen in Table II. Table III 
Discussion
This meta-analysis was conducted to analyze the clinical outcomes as described above of studies containing angiography and FFR guided PCI or iFR compared to FFR guided PCI. When comparing FFR and iFR with angiography outcomes, the main finding was a tendency towards FFR/iFR in all 4 clinical endpoints.
With the analysis of MACE having factored in all seven included studies, one could interpret these results to be the most convincing. When looking at the Odds Ratio, a tendency towards FFR becomes clear, and this is supported by the results of the individual components of MACE. Although the I² of MACE, death from any cause and unplanned revascularization were >50%, we decided not to exclude further studies in order to uphold a larger number of included patients.
FFR was first tested on its usefulness to determine the need for revascularization in intermediate coronary stenosis two decades ago (18) , and thereafter several studies have been carried out to show the safety of FFR and its superiority over angiography guided PCI. Such studies include FAME (Fractional Flow Reserve vs. Angiography for Guiding Percutaneous Coronary Intervention) (8) and DEFER (Deferral vs. performance of percutaneous coronary intervention of functionally non-significant coronary stenosis) (1). The later published FAME 2 study (Fractional Flow Reserve-Guided PCI vs. Medical Therapy in Stable Coronary Disease) further showed significantly better outcomes for FFR guided PCI combined with best medical treatment in comparison to best medical treatment alone (2) and was stopped prematurely due to the efficacy of the combined therapy. For additional information on the clinical outcomes of FFR guided PCI, the FAME 3 study is looking to compare this method with CABG surgery in patients with multivessel CAD (19) .
In contrast to our findings, a meta-analysis by Enezate et al (20) showed preference towards FFR and found a significant difference regarding MACE and MI at not exactly Furthermore, a meta-analysis by Zhang et al, which included studies with follow-ups from 9 up to 50.9 months, supports the superiority of FFR guided PCI (21 out in 2015, only one randomized study could be included, and the incorporation of the latest randomized trials may alter the results.
In addition, not all studies support the findings of the FAME study. The DEFER-DES study, which compared the 5-year outcomes of angiography and FFR guided PCI using drug eluting stents (DES), did not find any superiority for FFR guided DES implantation or routine DES implantation regarding the rate of MACE (11.6±3.0 and 14.2±3.3%, respectively (P= 0.55) (13) . A meta-analysis including only prospective studies from 2016 also found no significant 129 (58) 130 (59) 58 (26) 137 (62) 86 (39) 77 ( 336 (68) 323 (65) 163 (33) 333 (67) 226 (46) 143 (29) N.A.
(9)
Li a better discrimination for MACE and overall survival. The focus on the exact same follow-up point of time is a new aspect of this meta-analysis and improves the comparability of the included studies and their individual results. Excluding the retrospective studies from this current analysis prompted a change of results regarding MACE as well. By doing this, the trend moved stronger towards FFR, and the heterogeneity moved from high to low. This may indicate the existence of influencing factors in these three retrospective studies. With more studies being published in the future, in another meta-analysis carried out later one may alter the inclusion criteria and thus reduce the heterogeneity. One way could be to only include prospective RCT's or to exclude any study which had NSTEMI as an indication for PCI such as Layland et al (12) .
Another aspect of our meta-analysis was the difference between iFR guided and FFR guided PCI, since the absence of inferiority of iFR compared to FFR has been shown in the iFR-SWEDHEART (14) , as well as in DEFINE-FLAIR (15) . Both studies were published in 2017, after the accuracy of iFR was first compared to FFR in the ADVISE (ADenosine Vasodilator Independent Stenosis Evaluation) (5) and the CLARIFY (Classification Accuracy of Pressure-Only Ratios Against Indices Using Flow Study) study (6) . The statistical analysis had a high homogeneity throughout and showed that iFR was not inferior to FFR in all four entities. This must be seen in the context of iFR-SWEDHEART and DEFINE-FLAIR being the only multicenter, randomized, blinded trials focusing on FFR guided and iFR guided PCI, since iFR is a rather new technique. In addition, both studies reported on the observed discomfort of the patients during the procedure and showed significant lower numbers in chest discomfort (P<0.001) when using iFR. With both included studies showing equal diagnostic results it is not surprising for the meta-analysis to confirm the absence of inferiority of iFR. Nevertheless, it is important to validate the results of the individual trials, especially since to our knowledge a meta-analysis of iFR has not been performed at this point.
But, in order to compare angiography and iFR guided revascularization in a more direct way, we also conducted network meta-analysis. Although this network meta-analysis cannot be equated to a direct comparison, one can see that iFR is not inferior to angiography guided revascularization. This result is a very novel aspect of this paper and should be considered when talking about the best procedure when performing PCI.
As described above, iFR achieved similar results in comparison to FFR in similar study conditions. Nevertheless, further investigations should be conducted on iFR by itself in more complex situations, but also in a direct comparison to angiography and other treatment strategies for CAD, such as CABG.
Limitations of this meta-analysis are similar to the limitations of other meta-analyses. This includes the fact that we had no access to primary data, and the accuracy of our analysis depends on the accuracy of the primary sources. This meta-analysis includes prospective randomized controlled trials as well as retrospective non-randomized studies. Furthermore, the threshold for ischemia detection was not defined uniformly between the FFR studies (some studies used 0.75 and others 0.8). Lastly, it should be noted that the sample size of some of the studies was small and the populations for the three interventions all differed in size (angiography guided PCI included 8,403 patients; FFR guided PCI only included 5,223) Furthermore, we could only include two iFR studies in this meta-analysis, since iFR is a relatively new clinical procedure.
Overall, FFR guided PCI showed superiority in MACE during one year of follow up rates when comparing with angiography guided PCI. The high heterogeneity did not remain when excluding three retrospective studies and even reinforced the preference towards FFR. iFR guided PCI also did not show inferiority to FFR guided PCI, and thus one can assume iFR to be superior to solely angiography guided PCI as well. Because low heterogeneity and the small number of available studies limits the validity, further trials should be included in future analyses. A direct comparison of angiography and iFR may also be advised. When talking about those further studies, not only longer follow-up periods are needed to proof better outcomes for iFR and FFR guided coronary interventions regarding MACE, but also different clinical outcomes have to analyzed.
